Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Prediction of Long-Term Remission in Major Depressive Disorder Allows for Early Treatment Adjustments: Presented at ECNP - (DGDispatch)
    TopAbstracts in Depression 09/03/2008 - (DGNews)
    Brief, 3-Question Scale Effective in Uncovering Postpartum Depression - (DGNews)
    The ECNP Consensus Statement on Bipolar Depression - (DGNews)
    Montelukast Does Not Cause Depression or Suicide, American Lung Association Study Concludes - (DGNews)

    News archive

     Recent webcasts/CME - Depression
    Recognition and Management of Depression
    Understanding the Vital Link: Depression and Chronic Disease

    Webcasts/CME archive

     Recent cases - Depression
      A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
      Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report
      Dissecting the Determinants of Depressive Disorders Outcome: An in Depth Analysis of Two Clinical Cases
      Incomplete Oedipism and Chronic Suicidality in Psychotic Depression with Paranoid Delusions Related to Eyes
      Excessive Weight Gain after Remission of Depression in a Schizophrenic Patient Treated with Risperidone: Case Report

      Cases archive
        




      my personal edition > depression > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Mirtazapine Betters Major SSRIs for Treatment of Depression

      By Bruce Sylvester

      ATLANTA, GA -- May 27, 2005 -- A meta-analysis of clinical trials involving more than 2,500 subjects suggests that treatment of depression with mirtazapine (Remeron) results in a more rapid onset of clinical improvement compared to treatment with fluoxetine, paroxetine, and sertraline (all SSRIs), researchers reported here May 24th at the 158th Annual Meeting of the American Psychiatric Association (APA).

      "Mirtazapine is mechanistically a different kind of antidepressant than the more widely prescribed SSRIs or selective serotonin reuptake inhibitors," said presenter and lead investigator Michael Thase, MD, professor of psychiatry at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, United States. "One of the consequences of a mechanistic difference is that it may follow a different temporal characteristic. … There is about a one week earlier onset of benefit with mirtazapine."

      The investigators conducted a meta-analysis of data from 12 double-blind, randomized, controlled trials of mirtazapine versus SSRIs, involving more than 2,500 depressed patients. They compared remission rates (Hamilton Rating Scale for Depression -17 Item [HAMD-17] less than or equal to 7 or Montgomery-Asberg Depression Rating Scale [MADRS] less than or equal to 12) at weeks 1-6 and time-to-sustained remission using Kaplan-Meier graphing. They also calculated values of early response at week 6 as predictive of later remission.

      After 6 weeks, remission rates were 38.8% for mirtazapine and 34.7% for SSRI-treated groups. "The difference between the two groups was statistically significant in favor of mirtazapine at all assessments and across time (P less than or equal to .03; Logrank test). This advantage was largely explained by the onset of remission during the first three weeks of treatment (P less than or equal to .001)," according to the authors.

      They added that the results demonstrate that mirtazapine patients show a "significantly higher probability of response compared to SSRI-treated patients in the first three weeks of therapy" and that the sustained response indicated the same tendency.

      The study was supported by Organon International, Inc., which manufactures Remeron.


      [Presentation title: Remission With Mirtazapine Versus SSRIs: A Meta-Analysis. Abstract NR386.]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send